



EXPRESS MAIL NO. EV334001754 **US**

| | | |
|---|---|-----------------|
| RESPONSE TO RESTRICTION REQUIREMENT Address to: Commissioner for Patents Washington, D.C. 20231 | Attorney Docket | SMAR-012 |
| | First Named Inventor | C. Tudan et al. |
| | Application Number | 09/835,107 |
| | Filing Date | April 12, 2001 |
| | Group Art Unit | 1647 |
| | Examiner Name | B. Bunner |
| | Title: CXCR4 AGONIST TREATMENT OF HEMATOPOIETIC CELLS | |

TECH CENTER 1600/2900
JUL 01 2003
RECEIVED
#16
B.G.
7/16/03

Sir:

This is in response to the Restriction Requirement dated May 5, 2003.

Applicants hereby elect to prosecute the claims of Group I, claims 1-16, with traverse and Species T or SEQ ID. No. 11.

Applicants expressly reserve the right under 35 USC §121 to file a divisional application directed to the non-elected subject matter during the pendency of this application.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: June 25, 2003

By: 
Bret Field
Registration No. 37,620

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231